Lundbeck Presents Pipeline Update For Bifeprunox Studies

Lundbeck has announced the joint decision with its partner, Solvay to stop all joint R&D activities for Solvay’s compound – bifeprunox in development phase. The compound is intended for the maintenance treatment of schizophrenia.

The companies made this decision after evaluating the recent results from an interim analysis of pooled data, intended for a possible extension of the ongoing clinical phase III trial program. Efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia. Therefore, Lundbeck and Solvay judged that it would be futile to continue the studies.

Bifeprunox is a partial dopamine and serotonin 5-HT1A agonist designed to stabilize dopamine function in brain. It has been studied in more than 2,500 patients with schizophrenia in 14 efficacy and safety studies conducted throughout the world. Solvay is sais to be the originator of the compound.